Streetbeat News

Equity Actions

MAIA

REGN

MAIA Biotechnology has received FDA clearance for its Investigational New Drug application for THIO, a treatment for non-small-cell-lung-cancer. THIO will be evaluated in the US as part of the ongoing THIO-101 global phase 2 clinical trial. The drug is being tested with Regeneron Pharmaceuticals' cemiplimab to evaluate anti-tumor activity and immune response in patients. MAIA recently approved a share repurchase program of up to $800,000 of its Class A common stock through September 2024.

Portfolio Pulse from Nabaparna Bhattacharya

October 03, 2023 | 5:25 pm

JD

A whale investor has taken a bullish stance on JD.com (NASDAQ:JD), with 70% of the investors opening trades with bullish expectations and 30% with bearish. The whale has been targeting a price range from $22.5 to $38.76 for JD.com over the last 3 months. The price of JD is currently down -2.65% at $28.3. Loop Capital has maintained their Hold rating on JD.com, with a price target of $39.

Portfolio Pulse from Benzinga Insights

October 03, 2023 | 5:16 pm

CVX

A significant number of investors have taken a bearish stance on Chevron (NYSE:CVX), with 56% of the trades being bearish and 43% bullish. The total amount for puts is $2,676,272 and for calls is $802,030. Whales have been targeting a price range from $90.0 to $175.0 for Chevron over the last 3 months. Morgan Stanley and Mizuho have maintained their ratings on Chevron with price targets of $203 and $215 respectively.

Portfolio Pulse from Benzinga Insights

October 03, 2023 | 5:01 pm

VRAR

Glimpse Group Inc has announced an agreement for the purchase and sale of approximately 1.9 million shares of the company's common stock, according to an SEC 8K filing.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 4:48 pm

NOC

Northrop Grumman Inc.'s (NYSE:NOC) share price is currently at $441.35, after a 0.20% drop. Over the past month, the stock increased by 1.31%, but over the past year, it fell by 9.85%. The company's P/E ratio is lower than the aggregate P/E of the Aerospace & Defense industry, suggesting that the stock might be undervalued.

Portfolio Pulse from Benzinga Insights

October 03, 2023 | 4:45 pm

RIG

Josh Brown, a regular CNBC contributor, has sold his shares in Transocean (RIG).

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 4:38 pm

NKE

Jim Lebenthal, a regular CNBC contributor, has purchased shares in Nike (NKE).

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 4:33 pm

VRAR

Glimpse Group Inc has entered into a securities purchase agreement with accredited and institutional investors, according to a recent SEC 8K filing.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 4:28 pm

REGN

A significant investor has taken a bearish stance on Regeneron Pharmaceuticals (NASDAQ:REGN), with 70% of recent trades being bearish and 30% bullish. The trades have targeted a price range of $820.0 to $920.0 for Regeneron over the last 3 months. The current price of REGN is $818.04, with RSI indicators suggesting the stock may be approaching oversold. The next earnings are expected in 30 days.

Portfolio Pulse from Benzinga Insights

October 03, 2023 | 4:01 pm

INTC

A significant bearish stance has been taken on Intel (NASDAQ:INTC) by a large investor, as indicated by unusual options activity. The sentiment among these big-money traders is split between 44% bullish and 55% bearish. The whales have been targeting a price range from $26.0 to $38.0 for Intel over the last 3 months. Roth MKM and Rosenblatt have downgraded their actions on Intel to Neutral and Sell respectively.

Portfolio Pulse from Benzinga Insights

October 03, 2023 | 3:46 pm